Transcriptional profiling identifies a gene program active in metastatic prostate cancers that failed to respond to enzalutamide treatment.

Antiandrogen treatment is associated with heart and neurological problems and didn’t increase survival for this group of men, a U-M analysis finds.

A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline health care workers.

Researchers characterize three ways in which the gene FOXA1 mutates to trigger prostate cancer.

The largest study of its kind finds societal factors and access to quality care, rather than genetics, underlies higher prostate cancer mortality rates for black men.

A new study finds that U-M-designed compounds led to significantly smaller, slower-growing tumors.